Results-Driven: With Herrman & Herrman P.L.L.C., you gain a dedicated partner focused on achieving favorable outcomes for our clients
It is quick, cheap, and easy
Ribupatide vs Tirzepatide: Emerging Dual GIP/GLP-1 vs Approved Leader Evidence-based comparison of ribupatide (dual GLP-1/GIP agonist) and tirzepatide (dual GIP/GLP-1 agonist), including injectable, oral, and Phase 3 KaiNETIC program data
Lillys retatrutide, a triple agonist that hits the GLP-1, GIP, and glucagon receptors, met the primary endpoints of both Phase 3 trials but on terms that cooled the enthusiasm
Judge Marston has scheduled an evidentiary hearing for May 14, 2025, to evaluate scientific evidence linking the drugs to gastroparesis and other gastrointestinal issues, such as small bowel obstruction and gallbladder injuries